How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

1,836 results for

Wart Treatment

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

101. Immunotherapy in viral warts with intradermal Full Text available with Trip Pro

with Bacillus Calmette-Guerin. No recurrence was seen after lesions cleared.Patients were not followed up for more than 4 weeks after treatment. We could not estimate the cytokine levels or the peripheral blood mononuclear cell proliferation in response to Bacillus Calmette-Guerin/tuberculin purified protein derivative injections.Both intradermal Bacillus Calmette-Guerin and tuberculin purified protein derivative hold promise in the treatment of viral warts. Bacillus Calmette-Guerin may be more effective (...) Immunotherapy in viral warts with intradermal Current therapeutic modalities for viral warts are mostly ablative and are limited by high recurrence rates besides being unsuitable for numerous lesions. Immunotherapy has the potential to overcome these limitations.The aim of this study was to compare the effectiveness and safety of Bacillus Calmette-Guerin vaccine versus tuberculin purified protein derivative in the immunotherapy of warts.Patients received three doses of 0.1 ml of Bacillus

2018 Indian journal of dermatology, venereology and leprology Controlled trial quality: predicted high

102. A randomised controlled proof-of-concept trial of digoxin and furosemide in adults with cutaneous warts. Full Text available with Trip Pro

A randomised controlled proof-of-concept trial of digoxin and furosemide in adults with cutaneous warts. Topical ionic contraviral therapy (ICVT) with digoxin and furosemide inhibits the potassium influx on which DNA viruses rely for replication. Therefore, ICVT was hypothesized to be a potential novel treatment for cutaneous warts.To assess the clinical efficacy, safety and tolerability of ICVT in adults with cutaneous warts. The secondary objective was to gain insight into the underlying (...) working mechanism of ICVT.Treatment with ICVT was assessed for efficacy, safety and tolerability in a single- centre, randomized, double-blind, placebo-controlled phase IIA trial. Eighty adult patients with at least two cutaneous warts (plantar or common) were randomized to one of four treatments: digoxin + furosemide (0·125%), digoxin (0·125%), furosemide (0·125%) or placebo. The gel was administered once daily for 42 consecutive days. Predefined statistical analysis was performed with a mixed-model

2018 British Journal of Dermatology Controlled trial quality: predicted high

103. Cost analysis of Human Papillomavirus-related cervical diseases and genital warts in Swaziland. Full Text available with Trip Pro

and treatment in Swaziland. All identifiable direct medical costs were considered for cervical lesions, cervical cancer and genital warts, which were primary diagnoses during 2015. A mix of bottom up micro-costing ingredients approach and top-down approaches was used to collect data on costs. All costs were computed at the price level of 2015 and converted to dollars ($).The total annual estimated direct medical cost associated with screening, managing and treating cervical lesions, CC and genital warts (...) in Swaziland was $16 million. The largest cost in the analysis was estimated for treatment of high-grade cervical lesions and cervical cancer representing 80% of the total cost ($12.6 million). Costs for screening only represented 5% of the total cost ($0.9 million). Treatment of genital warts represented 6% of the total cost ($1million).According to the cost estimations in this study, the economic burden of HPV-related cervical diseases and genital warts represents a major public health issue in Swaziland

2017 PLoS ONE

104. Intralesional immunotherapy for the viral warts

Intralesional immunotherapy for the viral warts Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith (...) true for data from animal studies, which generally include various species, strains and treatment regimes, for which different true effects are likely to exist. The random-effects model takes into account both the within-study (sampling error) and between-study (differences in the true effect size) variance. Should the excessive between-study variance be very low or zero, the random-effects model will yield the same results as the fixed-effect model. For further details, see the and to pre-clinical

2020 PROSPERO

105. Intralesional immunotherapy in treatment of warts, a systematic review and meta-analysis

Intralesional immunotherapy in treatment of warts, a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation web address: Timing (...) is the typical model of choice for pre-clinical meta-analyses. This is because in the fixed-effect model, it is assumed that the differences in observed effect between studies is solely due to sampling error (i.e. differences in sample size), and that the true effect is the same (fixed) across all studies. However, this assumption is unlikely to hold true for data from animal studies, which generally include various species, strains and treatment regimes, for which different true effects are likely to exist

2017 PROSPERO

106. Ranpirnase eradicates human papillomavirus in cultured cells and heals anogenital warts in a Phase I study. (Abstract)

Ranpirnase eradicates human papillomavirus in cultured cells and heals anogenital warts in a Phase I study. Human papillomaviruses (HPV), the causative agents of anogenital warts, are the most prevalent sexually transmitted infectious agents, and wart treatment poses a persistent challenge. We assessed the safety and efficacy of treating HPV with ranpirnase, an endoribonuclease from the northern leopard frog that has been used extensively in Phase III oncology trials.As initial verification (...) of ranpirnase antiviral activity, we assessed its ability to eliminate papillomaviruses in cultured cells. To further assess its feasibility for treating anogenital warts in humans, we performed a Phase I study. Forty-two male volunteers with genital/perianal warts were treated topically with three different formulations of 1 mg/ml ranpirnase. Patients were monitored for 8 weeks or until healing. Four patients with HIV were treated in accordance with the compassionate programme but were not evaluated.In

2017 Antiviral Therapy

107. Efficacy of topical administration of Radix Euphorbiae Ebracteolatae on multiple plantar warts: A parallel randomized trial. (Abstract)

Efficacy of topical administration of Radix Euphorbiae Ebracteolatae on multiple plantar warts: A parallel randomized trial. To investigate the clinical efficacy of Radix Euphorbiae Ebracteolatae in treating multiple plantar warts.Twenty-eight patients with multiple plantar warts on both left and right feet were recruited. Warts on the left feet (treatment group) of all patients were externally treated with moderate ethanol extract of Radix Euphorbiae Ebracteolatae which was made of 30 g Radix (...) Euphorbiae Ebracteolatae putting into 100 mL of medical ethanol (75%). For the control group, moderate dose of 0.1% vitamin A acid ointment was externally applied onto the right-foot warts. The topical application of each treatment was conducted 3 times a day for both groups. After 4 and 8 weeks, the efficacy and side effects including skin erythema and blister were evaluated and observed.Compared with the pre-treatment, warts size of the control group was reduced after 8-week treatment (P<0.05). After 4

2017 Chinese journal of integrative medicine Controlled trial quality: uncertain

108. Significance of interferon gamma in the prediction of successful therapy of common warts by intralesional injection of Candida antigen. (Abstract)

Significance of interferon gamma in the prediction of successful therapy of common warts by intralesional injection of Candida antigen. Treatment of common warts remains a continuing challenge for both patients and physicians. Recently, intralesional immunotherapy by different antigens has proved efficacious in the treatment of warts, however, no definite predictive factors for successful therapy have been established. Herein, we evaluate the efficacy and safety of Candida antigen (...) in the treatment of common warts and the significance of interferon gamma (IFN-γ) in the prediction of successful therapy.The study included 54 patients with multiple common warts. A blood sample was collected from patients before therapy, cultured, and treated with Candida antigen for evaluation of IFN-γ. Candida antigen was directly injected into the largest wart at 2-week intervals until complete clearance or for a maximum of five treatments. Follow-up was made for 6 months to detect any recurrence.Complete

2017 International Journal of Dermatology

109. How I treat warts, hypogammaglobulinemia, infections, and myelokathexis (WHIM) syndrome. Full Text available with Trip Pro

How I treat warts, hypogammaglobulinemia, infections, and myelokathexis (WHIM) syndrome. Warts, hypogammaglobulinemia, infections, and myelokathexis (WHIM) syndrome is a genetic disease characterized by neutropenia, lymphopenia, susceptibility to infections, and myelokathexis, which describes degenerative changes of mature neutrophils and hyperplasia of bone marrow myeloid cells. Some patients present with hypogammaglobulinemia and/or refractory warts of skin and genitalia. Congenital cardiac (...) , such as development of bronchiectasis, anogenital dysplasia, or invasive cancer. The available therapeutic measures aimed at preventing the risk for infection in WHIM patients are discussed. We critically evaluate the diagnostic criteria of WHIM syndrome, particularly when WHIM syndrome should be suspected in patients with congenital neutropenia and lymphopenia despite the absence of hypogammaglobulinemia and/or warts. Finally, we discuss recent results of trials evaluating plerixafor, a selective antagonist

2017 Blood

110. Efficacy of Punch Reduction Prior to Cryotherapy in Patients with Viral Warts: A Case-Control Study in a Single Tertiary Center Full Text available with Trip Pro

matched with cryotherapy-only controls in terms of size and location of the wart. We compared the number and cost of treatments between the two groups.Eleven of the total 39 patients were treated with cryotherapy in addition to punch biopsy and the average number of treatments was 4.1±3.3 (mean±standard deviation). In a case-control study, the ratio value of cost was 2.9±3.6 in the experimental group and was 5.9±4.1 in controls (p<0.05).Punch biopsies can decrease the number and cost of treatment (...) Efficacy of Punch Reduction Prior to Cryotherapy in Patients with Viral Warts: A Case-Control Study in a Single Tertiary Center Cutaneous warts are a common complaint to visit dermatologic clinic and its course is variable, ranging from spontaneous resolution to a chronic condition refractory to treatment.To evaluate the efficacy and safety of punch biopsy for cutaneous warts.Thirty-nine patients who received punch biopsy for warts were reviewed through charts and photos. Among them, 15 were

2017 Annals of dermatology

111. Efficacy and Tolerability of Polyphenon E in “Difficult-to-Treat” Multiple Genital Warts in an HIV-Positive Male Subject Full Text available with Trip Pro

Efficacy and Tolerability of Polyphenon E in “Difficult-to-Treat” Multiple Genital Warts in an HIV-Positive Male Subject A 55-year-old man, nonsmoker, with a HIV-positive history came to our attention in February 2017. He was on treatment with StribildTM, 1 capsule daily (150 mg elvitegravir, 150 mg cobicistat, 200 mg emtricitabine, and 245 mg tenofovir disoproxil). The CD4+/CD8+ cellular count was 326/µL (normal values: 404-1,612); the CD3+/CD8+ cellular count was 819/µL (normal values (...) : 220-1,219). The CD4/CD8 ratio was 0.40 (normal value: >1). Several typical genital wart lesions were present at the penis shaft and at the level of the neck and the corona of glans. These lesions were present for 2 years. Several cryotherapy sessions (a total of 10 procedures) had been performed with partial success. At the initial visit a total of 5 lesions were present. Treatment with topical Polyphenon E 10% 3 times a day was prescribed and started. After 1 month of treatment the lesions were

2017 Case reports in dermatology

112. A Study of A-101 Topical Solution Administered Twice a Week in Subjects With Common Warts

Therapeutics, Inc. Information provided by (Responsible Party): Aclaris Therapeutics, Inc. Study Details Study Description Go to Brief Summary: The primary objective of this study is to evaluate the effectiveness of A-101 compared to Vehicle when applied to 1 Target common wart on the trunk or extremities twice a week. Condition or disease Intervention/treatment Phase Common Wart Drug: A-101 Topical Solution Drug: A-101 Vehicle Solution Phase 2 Detailed Description: The primary objective of this study (...) ) Actual Enrollment : 159 participants Allocation: Randomized Intervention Model: Parallel Assignment Masking: Double (Participant, Investigator) Primary Purpose: Treatment Official Title: A Randomized, Double-Blind, Vehicle-Controlled, Parallel Group Study of A-101 Topical Solution Applied Twice a Week in Subjects With Common Warts Actual Study Start Date : July 13, 2017 Actual Primary Completion Date : March 1, 2018 Actual Study Completion Date : March 1, 2018 Resource links provided by the National

2017 Clinical Trials

113. A Study to Evaluate the Safety and Efficacy of CLS006 Versus Vehicle in Subjects 2 Years of Age or Older With Cutaneous Common Warts

or disease Intervention/treatment Phase Cutaneous Common Warts Drug: CLS006 Drug: CLS006 Vehicle Phase 3 Study Design Go to Layout table for study information Study Type : Interventional (Clinical Trial) Actual Enrollment : 491 participants Allocation: Randomized Intervention Model: Parallel Assignment Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) Primary Purpose: Treatment Official Title: A Phase 3, Randomized, Double-Blind, Vehicle-Controlled, Multicenter Study (...) to Evaluate the Efficacy and Safety of CLS006 Versus Vehicle in Subjects 2 Years of Age or Older With Cutaneous Common Warts Actual Study Start Date : October 30, 2017 Actual Primary Completion Date : August 22, 2018 Actual Study Completion Date : November 7, 2018 Resource links provided by the National Library of Medicine related topics: Arms and Interventions Go to Arm Intervention/treatment Experimental: CLS006 Furosemide Topical Gel, 0.125% Drug: CLS006 Furosemide Topical Gel Experimental: CLS006

2017 Clinical Trials

114. Efficacy of Quadrivalent HPV Vaccine to Prevent Relapses of Genital Warts After Initial Therapeutic Response

population), with a heavy toll on patients' quality of life: low self-esteem and severe impairment of sexual well-being are common consequences. Treatments are painful and take time to achieve cure because of low complete remission (20 to 60%) and high recurrence rates (10 to 40%, 30% on average). Finding new means to reduce these recurrence rates thus seems justified. Infection with Human Papillomavirus (HPV) is responsible for EGW,other warts and some epithelial cancers. Out of two currently available (...) scheduled on site at M0, M2 and M6, 3 phone contacts at M1, M3 and M7, 2 clinical follow up visits on site at M9 and M12 + 1 unscheduled visit on site in case of EGW relapse during the study Condition or disease Intervention/treatment Phase Genital Warts Biological: Vaccination with Gardasil Biological: Injection of Normal Saline Phase 3 Study Design Go to Layout table for study information Study Type : Interventional (Clinical Trial) Estimated Enrollment : 300 participants Allocation: Randomized

2017 Clinical Trials

115. A systematic review and meta-analysis of acupuncture for flat warts

A systematic review and meta-analysis of acupuncture for flat warts Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g (...) true for data from animal studies, which generally include various species, strains and treatment regimes, for which different true effects are likely to exist. The random-effects model takes into account both the within-study (sampling error) and between-study (differences in the true effect size) variance. Should the excessive between-study variance be very low or zero, the random-effects model will yield the same results as the fixed-effect model. For further details, see the and to pre-clinical

2019 PROSPERO

116. Could the HPV vaccine prevent the recurrence of ano-genital warts?

Could the HPV vaccine prevent the recurrence of ano-genital warts? Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g (...) true for data from animal studies, which generally include various species, strains and treatment regimes, for which different true effects are likely to exist. The random-effects model takes into account both the within-study (sampling error) and between-study (differences in the true effect size) variance. Should the excessive between-study variance be very low or zero, the random-effects model will yield the same results as the fixed-effect model. For further details, see the and to pre-clinical

2019 PROSPERO

117. Ano-genital Human Papillomavirus (HPV) Infection, Precancerous Lesions and Genital Warts Among Danish Renal Transplant Recipients

Ano-genital Human Papillomavirus (HPV) Infection, Precancerous Lesions and Genital Warts Among Danish Renal Transplant Recipients Ano-genital Human Papillomavirus (HPV) Infection, Precancerous Lesions and Genital Warts Among Danish Renal Transplant Recipients - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have (...) reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Ano-genital Human Papillomavirus (HPV) Infection, Precancerous Lesions and Genital Warts Among Danish Renal Transplant Recipients The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT03018327 Recruitment

2017 Clinical Trials

118. Comparison Between Tuberculin Vaccine and Cryotherapy in Genital Wart Patients

: May 17, 2017 See Sponsor: Assiut University Information provided by (Responsible Party): Mena Ramsis Haleem, Assiut University Study Details Study Description Go to Brief Summary: Cutaneous and genital warts are common dermatological conditions caused by Human Papilloma Virus. Although it is a benign condition it causes disfigurement, has tendency to collect, can be transmitted to others, this makes adequate and timely treatment important, while many warts are resolve spontaneously over several (...) years, most patients seek treatment because the warts are unsightly and often tender or painful. Condition or disease Intervention/treatment Phase Genital Wart Biological: tuberculin Device: cryotherapy Phase 3 Detailed Description: Genital warts are highly contagious sexually transmitted diseases (STD) caused by infection of Human Papilloma Virus and, as the most common STD in developed countries, can currently be considered to be globally epidemic. It is estimated that the frequency of Human

2017 Clinical Trials

119. A Phase2 of A-101 Topical Solution in Subjects With Common Warts

Details Study Description Go to Brief Summary: The primary objective of this study is to evaluate the effectiveness of A-101 compared to vehicle when applied to 1 common target wart on the trunk or extremities. Condition or disease Intervention/treatment Phase Common Wart Drug: A-101 Topical Solution Phase 2 Detailed Description: The primary objective of this study is to evaluate the effectiveness of A-101 compared to vehicle when applied to 1 common target wart on the trunk or extremities (...) Purpose: Treatment Official Title: A Randomized, Double-Blind, Vehicle-Controlled, Parallel Group Study of A-101 Topical Solution Applied Once a Week in Subjects With Common Warts Actual Study Start Date : June 29, 2017 Actual Primary Completion Date : March 15, 2018 Actual Study Completion Date : March 15, 2018 Resource links provided by the National Library of Medicine related topics: Arms and Interventions Go to Arm Intervention/treatment Experimental: Active A-101 Topical Solution Drug: A-101

2017 Clinical Trials

120. Prevalence and incidence of external genital warts in a sample of Italian general female population. Full Text available with Trip Pro

the effectiveness of community clinical networks in investigating STI epidemiology among women from the general population, confirm the relevance of HPV vaccination programs among adolescents, and underscore the need of promoting safe sex, implementing early diagnosis, treatment and prevention of genital warts. (...) Prevalence and incidence of external genital warts in a sample of Italian general female population. The Human papillomavirus is the most common sexually transmitted virus worldwide. The objective of this study was to estimate: 1) the prevalence and the incidence of external genital warts (eGW) in a sample of women attending community outpatient clinics and 2) the total number of eGW cases in the Italian female population aged 15-64 years.A prospective study was performed for a 12-month period

2017 BMC Infectious Diseases

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>